Search results
Showing 16 to 30 of 78 results for cyclophosphamide
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
Idelalisib for treating chronic lymphocytic leukaemia (TA359)
Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia in adults.
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)
Evidence-based recommendations on fludarabine monotherapy for untreated chronic lymphocytic leukaemia in adults.
In development [GID-TA11571] Expected publication date: 26 March 2025
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
In development [GID-TA11091] Expected publication date: 20 August 2025
In development [GID-TA11164] Expected publication date: 17 September 2025
In development [GID-TA10912] Expected publication date: 16 July 2025
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)
Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone for untreated diffuse large B-cell lymphoma in adults.
Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)
Evidence-based recommendations on rituximab for treating follicular lymphoma in adults.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)
Evidence-based recommendations on bendamustine for treating chronic lymphocytic leukaemia in adults.
In development [GID-TA11495] Expected publication date: TBC
Obinutuzumab for untreated advanced follicular lymphoma (TA513)
Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.